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Abstract
This study details a method to evaluate the source size selection for small field intracranial
stereotactic radiosurgery (SRS) deliveries in Eclipse treatment planning system (TPS) for
AcurosXB dose calculation algorithm. Our method uses end-to-end dosimetric data to
evaluate a total of five source size selections (0.50 mm, 0.75 mm, 1.00 mm, 1.25 mm,
and 1.50 mm). The dosimetric leaf gap (DLG) was varied in this analysis (three DLG values
were tested for each scenario). We also tested two MLC leaf designs (standard and high-
definition MLC) and two delivery types for intracranial SRS (volumetric modulated arc
therapy [VMAT] and dynamic conformal arc [DCA]). Thus, a total of 10 VMAT plans and
10 DCA plans were tested for each machine type (TrueBeam [standard MLC] and Edge
[high-definition MLC]). Each plan was mapped to a solid water phantom and dose was cal-
culated with each iteration of source size and DLG value (15 total dose calculations for
each plan). To measure the dose, Gafchromic film was placed in the coronal plane of the
solid water phantom at isocenter. The phantom was localized via on-board CBCT and the
plans were delivered at planned gantry, collimator, and couch angles. The planned and
measured film dose was compared using Gamma (3.0%, 0.3 mm) criteria. The vendor-
recommended 1.00 mm source size was suitable for TrueBeam planning (both VMAT
and DCA planning) and Edge DCA planning. However, for Edge VMAT planning, the
0.50 mm source size yielded the highest passing rates. The difference in dose calculation
among the source size variations manifested primarily in two regions of the dose
calculation: (1) the shoulder of the high-dose region, and (2) for small targets (volume
≤ 0.30 cc), in the central portion of the high-dose region. Selection of a larger than opti-
mal source size can result in increased blurring of the shoulder for all target volume sizes
tested, and can result in central axis dose discrepancies in excess of 10% for target vol-
umes sizes ≤ 0.30 cc. Our results indicate a need for evaluation of the source size when
AcurosXB is used to model intracranial SRS delivery, and our methods represent a feasible
process for many clinics to perform tuning of the AcurosXB source size parameter.
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1 | INTRODUCTION
Stereotactic radiosurgery (SRS) has become a valuable treatment
modality to treat lesions within the brain1 and spine.2 In particular,
SRS provides a non-invasive treatment approach for unresectable
tumors (such as those in the eloquent cortex or otherwise deep-
seated tumors) or for patients who are otherwise not candidates for
surgery.3
Though SRS was first performed using a specialized device, now
commercially available as the GammaKnife, technological advances
have allowed for stereotactic therapies using the linear accelerator.
Several noteworthy advances have allowed for improved precision in
linear accelerator-based SRS: (1) the advent of treatment room
stereotactic imaging systems,4–7 including stereoscopic planar imag-
ing and cone-beam CT imaging, (2) improvements in patient support
devices, including 6 degree-of-freedom capabilities in the treatment
couch8 and improvements in couch movement precision, (3) increas-
ing availability of high-intensity photon modes,9–11 such as flatten-
ing-filter free photon modes with dose rates up to 2400 MU/min,
(4) high-definition multi-leaf collimator (MLC) systems with leaf
widths as narrow as 2.5 mm,12,13 and (5) optical monitoring systems
to track patient motion throughout the treatment course.14,15
Of course, the advances in the preceding paragraph all focus on
the treatment delivery, while an accurate end-to-end treatment
delivery relies on the marriage of the dose modeling within the
treatment planning system and the physical dose delivery within the
treatment room. Along these lines, the modeling of small-field dose
delivery has garnered much interest. The accurate measurement and
modeling of small-field dose delivery (i.e., field sizes < 3 9 3 cm2 in
water-equivalent media) has many challenges, including the effects
of the finite size of the radiation source, loss of charged particle
equilibrium (CPE), and sensitivity to small changes in field size for
perturbation factors of ion chambers used for measurement.16 The
AcurosXB algorithm gives a discretized solution to the linear Boltz-
mann transport equation,17–19 which provides improvements in
regions with loss of CPE, such as heterogeneity interfaces.20,21 How-
ever, the proper selection of source size within the AcurosXB algo-
rithm is still essential for the accurate modeling of small field
deliveries. The purpose of this study was two-fold: (1) to present a
clinically achievable method to evaluate the source size for small-
field dose calculation, and (2) to use the method to evaluate the
ideal source size setting within AcurosXB for flattening-filter energy
modes for two delivery platforms (Varian Edge and TrueBeam machi-
nes), MLC leaf models (Millennium120 HD-MLC and standard Mil-
lennium120 MLC), and delivery techniques for intra-cranial SRS
planning (DCA and VMAT).
2 | METHODS
2.A | Treatment planning and beam modeling
A total of 40 cranial SRS plans were generated for analysis in this
IRB-approved retrospective study. The analysis included two
machine types with different MLC models: (1) Varian Edge machine
(SN: 2003), which was installed in 2014 with Millennium120 HD-
MLC (central bank MLC leaf width 0.25 cm), and (2) Varian True-
Beam machine (SN: 2440), which was installed in late 2015 with
standard Millennium120 MLC (central bank MLC width 0.5 cm). For
each machine, plans were generated for two delivery modalities (dy-
namic conformal arc [DCA] and volumetric modulated arc therapy
[VMAT]). Thus, for each machine type, the analysis included 10 DCA
plans and 10 VMAT plans. The two different delivery modalities
were selected to highlight potential differences between intensity-
modulated deliveries (VMAT) and deliveries similar to MLC-defined
open fields (DCA).
All planning and dose calculations were performed using Varian
Eclipse (v. 13) TPS and AcurosXB dose calculation algorithm (v. 13;
1.0 mm isotropic dose calculation grid size and dose to medium cal-
culation setting). The dose to medium setting was used in accor-
dance with recently published recommendations from the NRG
physics group.22 The current study was designed to evaluate the
source size setting for small intracranial targets, with target volumes
as small as 0.03 cc (which corresponds to approximately 4 mm diam-
eter); in addition, several other studies have used smaller dose grid
size (i.e., less than 1.5 mm) as the standard for dose calculation com-
parisons when evaluating small-field dosimetry.23–26 With this in
mind, this study used 1.0 mm dose grid size for all dose calculations.
All planning was done with 6x-FFF beam energy with nominal dose
rate set to the maximum setting (1400 MU/min). The patient treat-
ment plan was generated with beam model parameters following the
vendor recommendations for source size (spot size setting of
1.00 mm in X- and Y-directions) and our current clinical values for
MLC parameters (i.e., dosimetric leaf gap (DLG) and MLC leaf trans-
mission value).7 The details of the relevant treatment planning data
(including target volume size and location) are shown in Table 1 for
Edge linac and Table 2 for TrueBeam linac.
To study the influence of source size on the calculated dose for
cranial SRS deliveries, a total of 5 AcurosXB beam models were cre-
ated for each machine type. The user can tune the source size in the
beam configuration module through varying the effective target spot
size value, which is entered by the user separately for X- and Y-
directions.19 All beam models used the same input measured data
(percent depth-dose, cross-line profiles, and output factors), with the
source size varied from 0.50 mm to 1.50 mm in 0.25 mm increments
for each machine type. Each beam model was then calculated sepa-
rately with its unique source size value. In addition to the source size
parameter, the DLG was also varied in the analysis. In Eclipse, the
DLG represents the TPS method for modeling of the rounded MLC
leaf end.19 For small MLC-defined fields, the leaf end modeling and
the potentially partial viewing of the finite size of the radiation
source along the central axis are inherently coupled. The DLG
parameter is not included within the Beam Configuration workspace
in ARIA v. 13; rather, it is included in the machine properties of the
RT Administration workspace. Nonetheless, the DLG parameter was
also varied in our analysis: three DLG values were included in the
modeling and calculation analysis for each machine type.
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All treatment plans were mapped to a water-equivalent slab
phantom, with total phantom dimensions of 15 cm 9 30 cm 9 30 cm
(Gammex Inc., Middleton, WI, USA). The isocenter was placed in the
center of the phantom, corresponding to 7.5 cm depth. Each treat-
ment plan was calculated for all combinations of source size beam
model and DLG value. Thus, for each treatment plan, a total of 15 dose
calculations were performed to sample the various source size and
DLG values for dose calculation. All dose calculations were performed
with the same monitor unit values determined during the original plan
optimization. After dose calculation was completed, planar dose
planes were exported for analysis (512 9 512 matrix resolution,
5 cm 9 5 cm matrix size).
2.B. | Gafchromic film measurements and
calibration
Film measurements using Gafchromic EBT3 film (Film Size:
20.3 9 25.4 cm2; Ashland Inc., Covington, KY, USA) were used to
evaluate the dose calculation accuracy in this study. Gafchromic film
was selected due to several attractive detector properties: extremely
high spatial resolution, large planar detection area, minimal direc-
tional dependence, and low energy dependence. In addition, Gaf-
chromic film and associated dosimetric analysis tools are widely
available to the radiation oncology community, making our methods
described here feasible for many clinics. The films were handled
according to the recommendations of AAPM Task Group 55.27 The
phantom localization and treatment procedure followed our clinical
process for intracranial SRS treatment delivery. Specifically, the
phantom and film plane (coronal plane at mid-phantom – 7.5 cm
depth) were localized using CBCT imaging prior to dose delivery
(125 kVp, Full-fan filter, 1 mm slice thickness), and all plans were
delivered at planned gantry, collimator, and couch angles. The aver-
age delay time between irradiation and film scanning was approxi-
mately 24 hr. Films were scanned in an Epson Expression 10000XL
flatbed scanner (Seiko Epson Corp, Nagano, Japan). All films were
scanned at the center of the scanner bed with resolution settings of
150 dot per inch and 48 bit RGB mode (16 bits per color channel). A
four-way flip method was used to average out any intrinsic light
source non-uniformity of the scanner. Dosimetric analysis was done
via green channel due to its superior sensitivity at the dose levels
larger than 10 Gy.28
The film calibration and dosimetric analysis was performed using
in-house software. Calibration films were irradiated in a nine square
dose pattern (area of 2 9 2 cm2 per square). The in-house calibra-
tion routine matches the film optical densities within each square to
the TPS calculated dose for the same beam geometry. Then, a
TAB L E 1 Relevant treatment planning data for (a) DCA and
(b) VMAT planning for Edge linac.
Patient number Disease site
PTV
volume
(cc)
Rx dose
(Gy)
Max film
plane dose
(Gy)
(a) Varian edge – DCA planning
1 Lt frontal 0.04 18 13.67
2 Rt ant frontal 0.07 18 12.65
3 Lt frontal 0.03 20 14.7
4 Lt frontal 0.23 18 15.69
5 Rt parietal 0.04 18 14.65
6 Lt inf frontal 1.29 18 14.49
7 Lt temporal 0.33 18 13.01
8 Cerebellar 0.48 18 18.55
9 Rt frontal 0.32 18 14.48
10 Rt parietal 0.19 18 14.45
(b) Varian edge – VMAT planning
1 Rt parietal 0.31 20 14.47
2 Rt ant frontal 0.07 18 16.63
3 Rt temporal 0.39 18 16.23
4 Rt CPA 0.86 16 16.43
5 Lt frontal 0.03 20 17.92
6 Lt frontal 0.23 18 16.16
7 Lt temporal 1.29 18 15.6
8 Lt inf frontal 0.33 18 17.21
9 Rt acoustic 0.75 13 12.36
10 Lt brainstem 0.51 9 10.64
TAB L E 2 Relevant treatment planning data for (a) DCA and
(b) VMAT planning for TrueBeam linac.
Patient
number
Disease
site
PTV
volume
(cc)
Rx dose
(Gy)
Max film
plane
dose (Gy)
(a) Varian truebeam – DCA planning
1 Rt temporal 2.01 18 14.66
2 Rt parietal 0.85 18 12.17
3 Rt frontal 0.82 18 12.07
4 Lt cerebeller 1.01 18 15.12
5 Rt parietal 1.93 18 14.13
6 Rt cerebeller 1.64 18 15.9
7 Rt thalamus 0.69 18 17.65
8 Lt frontal 0.46 18 13.78
9 Lt cerebeller 0.49 18 19.97
10 Lt frontal 0.38 18 12.03
(b) Varian truebeam – VMAT planning
1 Lt parietal 0.67 18 15.96
2 Rt precentral 0.78 18 15.88
3 Resection cavity SRS 13.9 15 13.99
4 Rt acoustic neuroma 0.43 13 14.13
5 Rt parietal 1.22 18 16.97
6 Lt temporal 0.24 18 16.84
7 Lt inf frontal 0.33 18 18.29
8 Lt temporal 1.29 18 14.94
9 Lt acoustic 1.16 12 11.34
10 Rt frontal 2.07 18 16.62
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calibration curve was generated using cubic polynomial least squares
fitting.
2.C. | Dose distribution analysis
The film measurements were compared to the calculated dose planes
using Gamma analysis.29 Typical Gamma analysis for patient-specific
IMRT QA may use distance-to-agreement criteria of 2–3 mm. How-
ever, the measurement scale (percentage of measurement points
with passing Gamma values) is often saturated if typical Gamma cri-
teria are used. To determine the appropriate Gamma analysis criteria
for this study, the Gamma analysis passing rate results for two repre-
sentative cases were logged for a variety of dose difference and dis-
tance-to-agreement criteria and compared to qualitative visual dose
profile analysis. The best agreement between passing rate result and
visual profile analysis was found for the following Gamma criteria:
3% dose difference and 0.3 mm distance-to-agreement. It should be
noted that these criteria are likely too strict for planning with con-
ventional target sizes. But, for very small targets such as those found
in intracranial SRS planning, a distance-to-agreement criteria of
1 mm is quite large relative to the lesion radius (for example, the
radius of a 0.5 cc spherical lesion is approximately 5 mm). See Fig. 1
for comparison of the Gamma criteria for one of the representative
cases. The value for dose threshold was set to 20% of the maximum
film plane dose, which corresponds to roughly 25% of the prescrip-
tion dose for these cases.
2.D. | Statistics
Gamma analysis passing rate results for each source size setting
were compared to passing rate results for vendor-recommended
source size setting using Student’s t-test, assuming two-tailed distri-
bution with P < 0.05 significant.
3 | RESULTS
3.A. | Film dosimetry results – gamma analysis
The Gamma analysis passing rate results for Edge linac are shown in
Fig. 2 (VMAT Planning) and Fig. 3 (DCA Planning). For each plot, the
(a)
(b)
(c) (d) (e) (f) (g)
(h)
F I G . 1 . Comparison of Gamma analysis criteria for one representative case from the study. The red regions in each Gamma map represent
failing pixels for the relevant Gamma criteria used. a, Planned dose (1.50 mm source size) plane with line profile geometry (green horizontal
line). b, Green channel film dose plane. c, Gamma map for 1%,1 mm criteria. d, Gamma map for 2%, 1 mm criteria. e, Gamma map for 3%,
1 mm criteria. f, Gamma map for 3%, 0.5 mm criteria. g, Gamma map for 3%, 0.3 mm criteria. h, Line profile comparing the AcurosXB planned
dose (1.50 mm source size) and green channel film dose. Note the disagreement between planned and measured dose in the shoulder of the
high-dose region. Gamma analysis using 1 mm dose-to-agreement criteria is insensitive to such discrepancy in the dose distribution, while
Gamma analysis with tighter distance-to-agreement criteria (e.g., 0.3 or 0.5 mm) shows failing points in the shoulder of the high-dose region
that match observed dose distribution discrepancies. The Gamma analysis criteria used for this study: 3%, 0.3 mm.
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whiskers indicate the maximum and minimum passing rates for each
source size setting and DLG value. The first, second, and third quartile
values for each combination of settings are also displayed on the plot.
Of the DLG settings tested for VMAT delivery with Edge linac, the
best overall agreement between measured and planned dose occurred
for DLG value of 0.090 cm. For 0.090 cm DLG value, the 0.50 mm
source size setting yielded the highest passing rate (mean  SD):
97.51  2.38% (P = 0.01). The passing rates (mean  SD) for the
other source sizes were as follows: 96.25  3.51% (0.75 mm,
P < 0.01), 93.72  4.96% (1.00 mm), 84.97  6.93% (1.25 mm,
P < 0.001), and 78.83  7.10% (1.50 mm, P < 0.001).
For DCA planning with DLG value of 0.090 cm, the highest pass-
ing rate occurred for vendor-recommended source size of 1.00 mm
(mean  SD): 99.41  0.99%. We note a sharper decline in passing
rate for larger-than-optimal source sizes (1.25 mm and 1.50 mm)
than for smaller-than-optimal source sizes (0.50 mm and 0.75 mm)
as shown in Fig. 2 and exhibited by the passing rate results
(mean  SD): 96.36  4.41% (0.50 mm, P = 0.04), 98.71  2.21%
(0.75 mm, P = 0.17), 89.96  7.17% (1.25 mm, P < 0.01),
81.79  8.30% (1.50 mm, P < 0.001).
The Gamma analysis passing rate results for TrueBeam linac are
shown in Fig. 4 (VMAT Planning) and Fig. 5 (DCA Planning). Of the
DLG settings tested for VMAT delivery with TrueBeam linac, the
best agreement between measured and planned dose occurred for
DLG value of 0.180 cm. For this DLG value, the 1.00 mm source
size setting yielded the highest average passing rate (mean  SD):
97.98  3.06%. The passing rate for the remaining source sizes with
0.180 cm DLG value were as follows: 95.02  4.68% (0.50 mm,
P < 0.01), 97.22  3.76% (0.75 mm, P = 0.066), 95.91  4.33%
(1.25 mm, P = 0.067), 92.46  5.88% (1.50 mm, P < 0.01).
For DCA planning with TrueBeam linac and DLG value of
0.180 cm, the highest mean passing rate occurred for source sizes
F I G . 2 . Gamma passing rate results for VMAT planning with Edge linac (HD-MLC). Note that the highest passing rates occur for the
0.090 cm DLG setting, and the optimal source size varies with DLG setting. For DLG value of 0.090 cm, the 0.50 mm source size results in
the highest passing rate (mean  SD passing rate of 97.51  2.38%). The vendor-recommended source size setting (1.00 mm) with the same
DLG value (0.090 cm) yields a lower mean passing rate result with larger variation–mean  SD passing rate 93.72  4.96%.
F I G . 3 . Gamma passing rate results for DCA planning with Edge linac (HD-MLC). The optimal source size for these data is 1.00 mm for DLG
value 0.090 cm (corresponding to the optimal DLG value for VMAT planning). For DLG values of 0.070 cm and 0.080 cm, the highest passing
rates occurred for calculations with 0.75 mm source size setting.
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of 1.00 mm (99.16  2.47%) and 1.25 mm (99.45  0.99%), with
no statistical significance in the difference in passing rate for these
two source sizes (P = 0.62). For all but one TrueBeam DCA case, the
1.00 mm and 1.25 mm source size dose calculations yielded passing
rates in excess of 99.50%. The mean  SD passing rate for the
remaining source sizes were as follows: 96.95  5.23% (0.50 mm,
P = 0.04), 98.62  3.63% (0.75 mm, P = 0.17), and 97.94  2.35%
(1.50 mm, P = 0.26).
3.B. | Film dosimetry results – dose profile
comparison
To highlight the variations in dose calculation with source size setting,
line profile comparisons were also generated for several representa-
tive VMAT cases for Edge and TrueBeam linacs. A comparison of
measured and calculated dose for multiple VMAT plans (one smaller
target size and one typical intracranial SRS target size) for Edge and
TrueBeam linacs is shown in Fig. 6. For Edge linac and smaller target
volume (0.07 cc) shown in Fig. 6 (a) we note two main differences in
the high-dose region among the source size calculations. First, there
is an increase in the blurring of the shoulder of the high-dose region
as the source size is increased. In addition, there is a reduction in the
magnitude of the central high-dose region as the source size is
increased. For this case, the 0.75 mm source size calculation yields
the best agreement with the measured dose. In the low dose region
(< 40% of peak dose) for this case, there is also some difference in
dose calculation among the calculations with various source sizes.
Similar behavior within the high-dose region for VMAT planning with
TrueBeam linac and smaller target volume (0.24 cc) is shown in Fig. 6
(c). For this case, the 1.00 mm source size calculation gives the best
F I G . 4 . Gamma passing rate results for VMAT planning with TrueBeam linac (Millennium-120 MLC). Note that the highest passing rates
occur for the 0.180 cm DLG setting, and the optimal source size varies with DLG setting. For DLG value of 0.180 cm, the 1.00 mm source
size yields the highest passing rates (mean  SD): 97.84  3.66%. For lower DLG value (0.160 cm), the average passing rate results for
0.50 mm, 0.75 mm and 1.00 mm settings were within 0.7% of one another. The highest passing rate for DLG value 0.160 cm occurred for
smaller source size – 0.75 mm setting with meanSD passing rate of 96.16  5.83%. For the larger DLG value (0.200 cm), the highest average
passing rate occurred for larger source size – 1.25 mm setting with mean  SD passing rate of 93.65  6.19%.
F I G . 5 . Gamma passing rate results for DCA planning with TrueBeam linac (Millennium-120 MLC). For 0.180 cm DLG value, the highest
passing rates occurred for source sizes of 1.00 mm (99.16  2.47%) and 1.25 mm (99.45  0.99%).
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agreement with measurement. For more typical intracranial lesions
with target volumes in the range of 0.5–1.0 cc (shown in Figs. 6 (b)
and 6 (d)), we note the same blurring of the shoulder of the high-dose
region, without the dramatic reduction in the magnitude of the cen-
tral high-dose region. For the larger volume case shown in Fig. 6 (b)
for Edge linac, the 0.50 mm source size setting yields the best visual
agreement between measured and calculated line profiles. For both
representative cases shown in Figs. 6 (c) and 6 (d) for TrueBeam linac,
the 1.00 mm source size setting yields the best visual agreement
between measured and calculated line profiles.
4 | DISCUSSION
The modern linac, with capabilities for online image guidance and
sub-millimeter end-to-end geometric accuracy, has become a
popular option for the delivery of stereotactic radiosurgery for
treatment of small intracranial lesions. Recently, advances in linac
design have included incorporation of stereotactic on-board imag-
ing systems,4–7 high-definition MLC,12,13 integrated 6 DOF couch,8
high-intensity flattening filter free energy modes,9–11 and surface
imaging systems for tracking.14,15 With improvements in the local-
ization and delivery systems, there remains a definite need for
accurate modeling of the small field dose delivery within the treat-
ment planning system. The purpose of this study was two-fold: (1)
to present a clinically achievable method to evaluate the source
size for small-field dose calculation, and (2) to use the method to
evaluate the ideal source size for flattening-filter energy modes for
two delivery platforms (Varian Edge and TrueBeam machines),
MLC leaf models (Millennium120 HD-MLC and standard Millenni-
um120 MLC), and delivery techniques (DCA and VMAT) used in
our clinic.
F I G . 6 . Comparison of measured dose (red solid line) with calculated dose for the source size settings tested for VMAT planning with Edge
and TrueBeam linacs. All calculations performed using optimal DLG value: 0.090 cm for Edge linac and 0.180 cm for TrueBeam linac. a, VMAT
planning for a small volume target (0.07 cc) with Edge linac. As the source size increases, the magnitude of the central high-dose region is
dramatically reduced (indicated by black arrow), the shoulder of the high-dose region exhibits blurring (light gray arrow), and the low dose region
also exhibits differences as a function of source size (gray arrow). b, VMAT planning for a typical volume target (0.86 cc) with Edge linac. Note
the similar blurring of the shoulder of the high-dose region (black arrow), but no difference in the magnitude of the central high-dose region. c,
VMAT planning for a smaller volume target (0.24 cc) for TrueBeam linac. Note the similar behavior in the central region, shoulder of the high-
dose region, and low dose region to profile comparison in (a). d, VMAT planning for a typical volume target (0.67 cc). Again, there remains
characteristic blurring of the shoulder of the high-dose region without variation in the magnitude of the central high-dose region.
176 | GARDNER ET AL.
Previous studies have provided validation of the AcurosXB dose
calculation algorithm for a variety of test cases. Vassiliev et al.com-
pared the AcurosXB dose calculation to Monte Carlo for 6 MV and
18 MV beam energy in a heterogeneity slab phantom, finding that
AcurosXB and Monte Carlo calculations agreed within 2% (local dose
difference) or 1 mm (distance to agreement).30 Stathakis et al. com-
pared small field dose calculation within and beyond heterogeneities
for several commercially available dose calculation algorithms (includ-
ing AcurosXB) to Monte Carlo results, finding that AcurosXB agreed
within 2% compared to Monte Carlo calculation in lung and bone
slab geometry.31 Kron et al. evaluated the accuracy of AcurosXB
dose calculation for situations with small MLC-defined segments and
larger secondary collimation settings.24 Their study included testing
the source size (focal spot size) for values of 0 mm, 1 mm, and
2 mm. They found agreement in output factor prediction between
AAA and AcurosXB to be within 1% for field sizes ≥ 1 9 1 cm2, and
found acceptable agreement between planned and measured doses
for focal spot size settings of 1 mm or less, DLG value of 1.4 mm,
and MLC transmission value of 1.4%. Fogliata et al. evaluated the
performance of AAA and AcurosXB for small MLC-defined open
fields and VMAT deliveries.32 Their study evaluated 4 VMAT plans
in total, but the plan details, including the arc geometry (single partial
arc of 140°) and total dose per plan (2 Gy), are not fully representa-
tive of typical intra-cranial SRS VMAT planning at our institution. In
addition, the target volume range ([0.3 cc, 7.0 cc]) does not encom-
pass the target volume size that is typically treated at our institution.
In particular, our institution tends to utilize multiple arc delivery with
typical prescription dosing (on the order of 18 Gy), and the volume
of the targets at our institution can be less than 0.10 cc. Our study
results indicate that the influence of the source size selection on the
dose calculation accuracy is of particular interest for target volume
sizes less than approximately 0.30 cc. As shown in Fig. 7, use of
source sizes larger than recommended (e.g., 1.25 mm and 1.50 mm
in this study) can result in further reduction in Gamma Analysis pass-
ing rates for target volume sizes less than approximately 0.30 cc. In
addition, the Fogliata et al. study evaluated the algorithm
performance with a conventional linear accelerator (Varian Clinac
2100iX) with standard width MLC (Millennium-120) and standard
energy mode (6 MV). In this study, we evaluate various source size
settings in AcurosXB for dose calculations of small intra-cranial tar-
gets for VMAT and DCA planning with two linear accelerator deliv-
ery platforms utilizing flattening filter-free energy mode (6 MV-FFF).
For both AcurosXB and AAA, the Eclipse treatment planning sys-
tem utilizes a dual-source dose calculation model, consisting of the
primary source and extra-focal source.19 The extra-focal source is a
Gaussian plane source positioned at the edge of the flattening filter
distal to the target. For flattening-filter free beams, such as the 6
MV-FFF energy mode evaluated in this study, the extra-focal source
modeling is disabled, since the principal element contributing to the
need for extra-focal modeling (i.e., the flattening filter) is not present.
The primary source can be tuned using the effective target spot size
parameter (entered separately for X- and Y- directions in the jaw
coordinate system). The finite size of the primary source is modeled
via Gaussian smoothing of the primary energy fluence, with the spot
size parameter representing the FWHM of the Gaussian filter in the
isocenter plane. The spot size parameter is coupled with the beam-
limiting device (i.e., jaw or MLC). If the vendor-recommended spot
size parameter (1.00 mm in X- and Y-directions) is used for Acur-
osXB beam modeling, then the actual source size employed during
dose calculation depends on the beam-limiting device: (1) if the field
is delimited by jaws alone, then 1.00 mm is used for X- and Y-direc-
tions, and (2) if MLC are used, then the following are used: 1.50 mm
(X-direction) and 0 mm (Y-direction).19 In the current study, we note
the difference in behavior for the two MLC models tested. For Mil-
lennium-120 MLC with 0.180 cm DLG value, the vendor-recom-
mended 1.00 mm source size was suitable for both VMAT planning
DCA planning. For Millennium-120 HD-MLC, the 0.50 mm source
size setting yielded the highest passing rate results for VMAT plan-
ning, while the was 1.00 mm source size yielded the highest passing
rate results for DCA planning. The differences in these results high-
light the need to perform machine- and treatment intent-specific
testing, particularly for small-field delivery using VMAT. When
F I G . 7 . Difference in Gamma Analysis
passing rate for each source size tested
relative to the vendor-recommended
source size (1.00 mm) for all cases tested
(all machine types and all delivery types).
Note the sharp decrease in passing rate for
smaller target volume size
(volume ≤ 0.30 cc) for source sizes larger
than the recommended 1.00 mm value
(1.25 mm and 1.50 mm).
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selecting the optimal source size value for a clinical delivery system,
it is essential to understand the downside of using smaller source
size settings for AcurosXB (relative to the nominal recommended
source size). We note that our study findings indicate no statistically
significant difference in calculation time among the source sizes
tested. However, choosing a source size setting that is too small
could lead to overestimation of the size of the shoulder of the high-
dose region. Thus, since the prescription isodose line is often in the
shoulder of the high-dose region, this could lead to an overestima-
tion of the prescription isodose cloud in the planning system. If a
tradeoff is needed during commissioning and beam modeling, the
user should determine whether underestimating or overestimating
the dose level of the shoulder of the high-dose region is preferable.
For our clinic, there was significant interest in using one beam model
for each machine. Namely, we looked to avoid using a separate
beam model for VMAT and DCA deliveries. It is worth noting that
there was no statistically significant difference between the gamma
analysis passing rates for 0.50 mm and 0.75 mm (P = 0.057) source
size values for Edge VMAT delivery, and also no statistically signifi-
cant difference between the gamma analysis passing rates for
0.75 mm and 1.00 mm (P = 0.175) source size values for Edge DCA
delivery. In addition, qualitative line profile analysis indicated equiva-
lent agreement between planned and measured dose for the
0.75 mm and 1.00 mm source size data for DCA delivery, as well as
between the 0.50 mm and 0.75 mm source size data for VMAT
delivery. Thus, we evaluated all of our clinical goals, including: (1)
avoid under coverage of the tumor due to overestimation of the pre-
scription isodose cloud, (2) if at all possible, use a single beam model
for the Edge machine, and (3) use both quantitative gamma analysis
and qualitative line profile analysis. Taking all of these factors into
account, the 0.75 mm source size was chosen for our institutional
Edge beam model, which included use for both VMAT and DCA
deliveries. Our study using Gafchromic EBT3 film and solid water
slab phantom provides a feasible and effective method for evaluating
beam modeling parameters such as source size and DLG during
machine commissioning.
The use of gamma analysis for IMRT QA has been the subject of
much scrutiny.33–38 In particular, gamma analysis using traditional cri-
teria for distance-to-agreement (on the order of 2–3 mm) and dose
difference (on the order of 2–3%) may not be sensitive to clinically
meaningful dose errors when per-beam IMRT analysis is used. We
note several considerations regarding the use of gamma analysis in
this study. First, gamma analysis provides a binary result for each
pixel (i.e., the pixel either passes or fails the test), and the gamma
analysis does not discriminate between delivered dose that is higher
or lower than the planned dose. For this reason, commissioning of
small-field deliveries should not rely on gamma passing rates alone;
rather, the gamma map and line profile analysis should also be used
to give a better understanding of the agreement between planned
and measured doses. In this study, we present gamma analysis pass-
ing rates and line profile analyses of representative cases. Second, all
dose distributions analyzed in this study are composite dose distribu-
tions. The dose distributions for each arc are summed in the
phantom just as they would in a clinical patient. We believe this
avoids one major issue with typical IMRT QA, which is the lack of
correlation between per-beam planar measurements and clinically
meaningful dose errors. Third, our institutional film analysis program
allowed for the use of relatively small distance-to-agreement criteria
(on the order of 0.3 mm) for these cases; similar distance-to-agree-
ment criteria (0.5 mm) was previously used to validate GammaKnife
dosimetry.39 The details of our institutional practice for SRS/SBRT
QA using Gafchromic film have been published40; of note, the film
analysis procedure includes a rigid registration routine using mutual
information as the similarity metric. For each case, the result of the
film analysis image registration is reviewed. It should be noted that
the use of such small distance-to-agreement criteria (0.3 mm) in the
gamma analysis was intended for use in this study and is not part of
our institutional clinical routine; the use of such small distance-to-
agreement relies on (1) robust image registration between the
planned and measured dose planes, and (2) sufficiently fine resolu-
tion for both planned and measured dose planes. For this reason, we
used 1 mm isotropic dose grid setting (the lowest allowed in Eclipse
TPS), and exported all plans using 0.098 mm pixel size. Though not
all gamma analysis criteria are sensitive to meaningful dose errors,
we believe we have shown the 3% dose difference and 0.3 mm cri-
teria as employed in this study to be sensitive to meaningful dose
errors in cranial SRS deliveries (see Fig. 1). However, we again stress
the usefulness of other complementary analysis tools, such as the
use of the gamma map and line profile analysis, and caution against
the use of gamma passing rates alone in the commissioning or verifi-
cation process for SRS VMAT and DCA deliveries. The AAPM Task
Group 119 introduced the concept of confidence limits for determin-
ing appropriate bounds of IMRT QA results.41 The formula used for
calculating the confidence limit is as follows: Confidence
Limit = ∣mean∣ + 1.96r Applying this formula to the VMAT film
dosimetry data for (1) HD-MLC (DLG = 0.090 cm, Source
Size = 0.50 mm) yields a confidence limit of 92.9% for lower bound
of passing rate, and (2) for Millennium-120 MLC (DLG = 0.180 cm,
Source Size = 1.00 mm) yields a confidence limit of 90.7% for lower
bound of passing rate. These confidence limits are not generally
applicable to all clinics, since they are based on a single institutional
QA dataset. Rather, these confidence limits can be used as a qualita-
tive reference when performing similar measurements for commis-
sioning of small-field VMAT deliveries.
The dose profile comparison indicated two important regions of
dose distribution variation resulting from tuning of the calculation
model source size: the shoulder of the high-dose region and the cen-
ter of the high-dose region. First, we note differences in the shoul-
der of the high-dose region (Fig. 6). As the source size increases, we
note the blurring of the shoulder of the high-dose region, which
occurred for the entire range of target volume sizes tested. This
blurring is of particular importance for intracranial SRS planning,
since the prescription isodose line is typically in the shoulder region
of the dose distribution to allow for sharp dose gradients outside
the target volume. Any discrepancy in the full width at 75–85% of
the peak dose indicates that the planning system is not correctly
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calculating the volume of the prescription isodose cloud. In addition,
for very small targets (less than approximately 0.30 cc), the central
portion of the high-dose region is also impacted by the source size
selection. As shown in Fig. 8, improper selection of the source size
in the dose calculation model can result in meaningful reduction in
isocenter dose for lesions smaller than approximately 0.30 cc. For
very small targets (lesions less than 0.10 cc), we note the presence
of discrepancies in isocenter dose up to 10.8%. Of the lesions ana-
lyzed in this study with volume less than 0.10 cc, five of the six
lesions had dose discrepancies in excess of 8%. These findings rein-
force the need to perform dosimetric verification of the dose calcu-
lation model at the smallest anticipated target volume size. If the
proper source size is not used in the dose calculation model, one
potential mitigation strategy would include using a slightly larger
margin for intra-cranial lesions. Line profile analysis in this study indi-
cates that discrepancies between dose calculations with 0.5 mm and
1.5 mm source size setting can routinely approach 1 mm in the
shoulder of the high-dose region. Though an explicit recommenda-
tion on lower bound for target size treated for each MLC type is
beyond the scope of this work, we have shown that proper tuning
of the source size and DLG parameters allow for reliable modeling
of the dose delivery with (1) HD-MLC to target volumes as small as
0.03 cc, and (2) Millennium-120 MLC to targets volumes as small as
0.24 cc. Other factors, such as the resolution of imaging systems
used for planning and localization (e.g., CT, MRI, and CBCT) and the
lower bounds of the dose calculation grid size, also play a role in
determining the lower bound for target size.
Of note, this study included analysis of conventional and high-
definition MLC models. We note several interesting differences in
the passing rate trends for the Edge linac and TrueBeam linac among
the entire set of source sizes tested. First, the optimal source size
and DLG value resulted in similar mean passing rates for each deliv-
ery modality: (1) for VMAT: 97.51  2.38% (Edge) vs
97.84  3.66% (TrueBeam; P = 0.81), and (2) for DCA:
99.41  0.99% (Edge) vs 99.16  2.47% (TrueBeam; P = 0.77). We
believe these similar passing rate results (and corresponding line
profile analyses) for the optimal source size and DLG value indicate
that the optimal beam model can give similar agreement between
planned and measured doses for each MLC type. However, there
exists a sharper decrease in passing rate for the Edge data for sub-
optimal selection of source size and DLG setting. It is worth noting
the differences in lesion geometry for the two MLC types. For the
Edge linac, there were seven lesions (out of 20 total) below 0.30 cc,
with only one such lesion for the TrueBeam linac. In addition, there
were nine lesions above 1 cc for the TrueBeam linac, with only two
such lesions for the Edge linac. This was intentional, to ensure the
lesion volumes were chosen to reflect the intended clinical use of
each MLC type. As has been shown in previous studies, the HD-
MLC is better able to deliver stereotactic treatments to small
intracranial lesions as compared to standard width MLC.42 As shown
in Figs. 7 and 8, the dose calculation appears to be most sensitive to
variations in source size at the smallest lesion sizes (in this study, we
deem the lesion small if the volume is less than approx. 0.30 cc).
Under 0.30 cc, variations in source size lead to discrepancies in both
the shoulder and central area of the high-dose region. Thus, though
our results indicate no statistically significant difference in the agree-
ment between planned and measured doses in this study for the
optimal Edge and TrueBeam beam models, any selection of subopti-
mal source size (and also DLG value) has the potential to be more
impactful, on average, for deliveries involving smaller lesions. In addi-
tion, our results indicate a difference in optimal source size for
VMAT delivery with these two MLC models, which we attribute to
the combination of differences in the MLC leaf end design and the
method by which the TPS models the finites size of the source (i.e.,
a Gaussian convolution blurring). We believe that our study repre-
sents the first reporting of the differences in dose calculation as a
function of source size with changes in MLC model for Eclipse TPS.
In addition, we note the difference in optimal source size as deter-
mined using film dosimetry for intensity-modulated delivery (VMAT)
and open-field delivery (DCA). Some previous studies have charac-
terized the effects of source size using small MLC-defined open
fields with beams at normal incidence and comparing to Monte Carlo
F I G . 8 . Comparison of isocenter dose
for Edge and TrueBeam linacs for VMAT
and DCA planning. Dose difference is the
isocenter dose 1.50 mm source size
relative to isocenter dose for optimal
VMAT source size (0.50 mm for Edge linac
and 1.00 mm for TrueBeam linac). The
blue dashed lines indicate region of target
volume less than 0.30 cc and dose
difference less than 3%. The black solid
lines indicate region with target volume
less than 0.15 cc and dose difference less
than 5%. The largest dose discrepancy was
10.80% for 0.03 cc volume target.
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calculations, film dosimetry, or other high-resolution dosimetric
data.17,24,32 The difference in the film dosimetry results in the cur-
rent study for VMAT and DCA planning groups (particularly for Edge
linac with high-definition MLC) underscore the need to extend the
dose calculation model analysis to include intensity-modulated
deliveries.
The modeling of small-field deliveries within Eclipse is a combina-
tion of the field-specific output factor (determined from the collima-
tor back scatter factor (CBSF) table in Eclipse), modeling of the MLC
leaf end (primarily determined from the DLG value in Eclipse), and
the modeling of the source. This study analysis included evaluation
of the latter two parameters, but did not fully consider the effects
of the CBSF table. However, all beam models were generated using
output factor down to jaw sizes of 1 9 1 cm2, with small field data
measured using a stereotactic field diode. It is important to note that
all plans analyzed in this study utilized jaw settings larger than
1 9 1 cm2; the smallest jaw setting for this study was
1.6 cm 9 1.4 cm (X by Y). Additionally, MLC-defined small field
delivery was validated for field sizes down to 5 mm 9 5 mm using
multiple detectors. During commissioning, all small field data was
measured multiple times and cross-compared to several detectors
for validation, and the calculated output factor data compared favor-
ably with internal Monte Carlo testing. Thus, though we don’t explic-
itly consider the effects of the CBSF table in this study, all beam
models were generated with the appropriate selection of detector
and the data was validated in multiple ways. This study uses film
dosimetry as the primary means to evaluate the accuracy of the
dose calculation model. In our clinic, we perform film-based QA of
all intensity-modulated stereotactic deliveries. In general, the uncer-
tainty in Gafchromic film dosimetry arises from issues with film uni-
formity, scanner uncertainties, background variations, film handling,
and registration between film and calculated dose planes. Our meth-
ods, including strict protocols for handling the films, scanning the
films in multiple orientations, and keeping scan delay times consis-
tent at 24 hr, minimize the uncertainty in the film result. Through
internal testing, we have determined the uncertainty in film absolute
dose for small targets to be within 2% at all points of the calibration
curve for green channel. Further details on our institutional practice
for SRS/SBRT film QA have been published.
5. | CONCLUSION
This study highlights the need for tuning of the radiation target
source size for the AcurosXB dose calculation algorithm in the con-
text of intracranial SRS dose delivery using DCA and VMAT. In par-
ticular, we note the differences in optimal source size values for
high-definition (2.5 mm leaf width) and standard (5 mm leaf width)
MLC with flattening-filter free delivery. Improper selection of the
source size can affect the accuracy of the shoulder of the high
shoulder for a wide range of intracranial target sizes, and can also
have a drastic effect on the magnitude of the central high-dose
region for very small targets (target volume ≤ 0.30 cc).
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